JZJuliette Zwaveling

Juliette Zwaveling

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Juliette Zwaveling has a total of 121 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Validation of a Text-Mining Tool for Extracting Routine Clinical Care Data in Early-Stage Resectable Non–Small Cell Lung Cancer

    by Hanieh Abedian Kalkhoran, Tobias Martinot, Lydia H.N. Schonewille, Melek Huyuk, Michiel H.J. Huigen, Henk-Jan Guchelaar, Danielle Cohen, Egbert F. Smit, Juliette Zwaveling

    PURPOSE: Manual chart review (MR) of electronic health records (EHRs) is time-consuming, error-prone, and limits the reproducibility and scalability of real-world data (RWD) research. Automation and standardization using natural language processing (NLP) could improve efficiency and scalability. CTcue is an NLP-based software platform designed to extract structured and unstructured data from EHRs. This study evaluated the accuracy and efficiency of CTcue versus MR in patients with early-stage resectable non–small cell lung cancer (NSCLC). METHODS: Included were all patients with stage I to III NSCLC who underwent lung resections between January 2018 and December 2021 at the Leiden University Medical Center, the Netherlands. Demographics, tumor characteristics, treatment, and outcomes were collected. CTcue performance was compared with MR using weighted F1-scores, accuracy, precision, and recall for categorical variables and Bland-Altman analysis for continuous variables. RESULTS: Eighty-five patients (70.2% of patients from the manual cohort) were identified by both methods and included in the comparison. CTcue achieved weighted F1-scores >0.85 for seven of 15 categorical variables, including sex, tumor location, and deceased status, although some scores were based on low number of observations in both cohorts. Lower performance was observed for variables with varying terminology in documentation, such as Eastern Cooperative Oncology Group status and pathological N-stage. Continuous variables showed negligible mean differences, indicating good agreement. Survival outcomes were identical in both data sets. CONCLUSION: CTcue performance for patient selection was lower than anticipated. However, it enables accurate, efficient extraction of structured and unstructured EHR data in early-stage NSCLC. Manual validation remains necessary for variables with varying terminology. Further development of artificial intelligence-based tools—particularly for free-text data extraction—will be crucial to enhance the accuracy and scalability of future RWD research.

  • Open Access

    Model-informed approaches to develop drug cost-saving dosing strategies for pembrolizumab

    by Yan Wang, Laura H. Bukkems, Johan G.C. van Hasselt, Marie-Rose Crombag, Daphne Dumoulin, Jeroen J.M.A. Hendrikx, Willemijn Theelen, Tom van der Hulle, Ellen Kapiteijn, Juliëtte Zwaveling, et al.

  • Open Access

    Model-Informed Approaches to Develop Cost-Saving Dosing Strategies for Pembrolizumab

    by Yan Wang, Laura H. Bukkems, J.G. Coen van Hasselt, Marie-Rose Crombag, Daphne W. Dumoulin, Jeroen J.M.A Hendrikx, W.S.M.E. Theelen, Tom van der Hulle, Ellen Kapiteijn, Juliëtte Zwaveling, et al.

    Background: The increasing use of pembrolizumab in oncological treatments results in substantial healthcare costs and the subcutaneous (SC) pembrolizumab formulation remains expensive. To evaluate alternative SC pembrolizumab dosing strategies that reduce costs while maintaining equivalent exposure and improving patient convenience.Methods: A previously published population pharmacokinetic model was used to evaluate alternative dosing strategies achieving exposure equivalent to the intravenous (IV) 2 mg/kg Q3W dosing (reference) compliant with FDA guidelines and reducing costs (Dutch price). First, extended fixed dosing intervals irrespective of bodyweight were investigated. Second, body-weight-adjusted dosing intervals were evaluated. Finally, we explored to inject SC formulation (790 mg) intravenously.Results: Identified alternative regimens included SC 790 mg Q7W for all patients; SC 790 mg Q8W (85 kg); and IV administration of 790 mg Q9W using the SC formulation. The extended-interval SC regimen (790 mg Q7W) would reduce annual cost to €85,000 (-14%). A bodyweight-adjusted SC strategy would reduce yearly cost from €99,166 to €85,000 (-14%; 55 - 85 kg) and to €74,375 (-25%; <55 kg). Using the SC formulation intravenously can potentially save annual costs by €33,055 (-33%). In addition, extracting 5 doses of 150 mg Q3W out of one 790 mg SC dose could reduce the annual costs even to €39,666 (-60%).Conclusions: Dose interval extension of subcutaneous pembrolizumab maintains equivalent exposure and complies with regulatory requirements. Intravenous administration of the subcutaneous formulation is a promising highly cost-effective intervention but requires prospective safety investigation before implementation.

  • Severe acute refractory hyperkalaemia associated with liposomal amphotericin B infusion

    by Gabriëlla von Kreijfelt, Linda Davidson, Yara Joanne Holtrust, Maarten Arends, Juliëtte Zwaveling


  • The effectiveness of pembrolizumab maintenance with or without pemetrexed after induction treatment for advanced non-squamous Non–Small-Cell Lung cancer

    by Bas Jm Peters, Esmée van Geffen, Doranne Hilarius, Stephan Böhringer, Juliëtte Zwaveling, Esther Dronkers, Cor H van der Leest, Hans Jm Smit


  • Open Access

    Development and Portability of a Text Mining Algorithm for Capturing Disease Progression in Electronic Health Records of Patients With Stage IV Non–Small Cell Lung Cancer

    by M.V. Verschueren, H. Abedian Kalkhoran, M. Deenen, B.E.E.M. van Den Borne, J. Zwaveling, L.E. Visser, L.T. Bloem, B.J.M. Peters, E.M.W. van de Garde

    PURPOSE: The objective was to develop and evaluate the portability of a text mining algorithm for prospectively capturing disease progression in electronic health record (EHR) data of patients with metastatic non–small cell lung cancer (mNSCLC) treated with immunochemotherapy. METHODS: This study used EHR data from patients with mNSCLC receiving immunochemotherapy (between October 1, 2018, and December 31, 2022) in four Dutch hospitals. A text mining algorithm for capturing disease progression was developed in hospitals 1 and 2 and then transferred to hospitals 3 and 4 to evaluate portability. Performance metrics were calculated by comparing its outcomes with manual chart review. In addition, data were simulated to come available over time to assess performance in real-time applications. Median progression-free survival (PFS) was calculated using the Kaplan-Meier method to compare text mining with manual chart review. RESULTS: During development and portability, the text mining algorithm performed well in capturing disease progression, with all performance scores >90%. When real-time performance was simulated, the performance scores in all four hospitals exceeded 90% from week 15 after the start of follow-up. Although the exact progression dates varied in 46 patients of 157 patients with progressive disease, the number of patients labeled with progression too early (n = 24) and too late (n = 22) was well balanced with discrepancies ranging from –116 to 384 days. Nevertheless, the PFS curves constructed with text mining and manual chart review were highly similar for each hospital. CONCLUSION: In this study, an accurate text mining algorithm for capturing disease progression in the EHR data of patients with mNSCLC was developed. The algorithm was portable across different hospitals, and the performance over time was good, making this an interesting approach for prospective follow-up of multicenter cohorts.


  • Open Access

    Model-Informed Development of a Cost-Saving Dosing Regimen for Sacituzumab Govitecan

    by Dirk J. A. R. Moes, Jeroen J. M. A. Hendrikx, Henk-Jan Guchelaar, Ron H. J. Mathijssen, J. L. Bakker, Vincent O. Dezentjé, Nikki de Rouw, Nielka P. van Erp, Egbert F. Smit, Michel M. van Den Heuvel, et al.

    Background The antibody–drug conjugate sacituzumab govitecan is approved for metastatic triple-negative breast cancer and has shown promising results in various other types of cancer. Its costs may limit patient access to this novel effective treatment modality. Objective The purpose of this study was to develop an evidence-based rational dosing regimen that results in targeted drug exposure within the therapeutic range while minimizing financial toxicity, to improve treatment access. Patients and Methods Exposure equivalent dosing strategies were developed based on pharmacokinetic modeling and simulation by using the published pharmacokinetic model developed by the license holder. The alternative dose was based on the principle of using complete vials to prevent spillage and on the established non-linear relationship between body weight and systemic exposure. Equivalent exposure compared to the approved dosing regimen of 10 mg/kg was aimed for. Equivalent exposure was conservatively defined as calculated geometric mean ratios within the 0.9–1.11 boundaries for area under the concentration–time curve (AUC), trough concentration (Ctrough) and maximum concentration (Cmax) of the alternative dosing regimen compared to the approved dosing regimen. Since different vial sizes are available for the European Union (EU) and United States (US) market, because body weight distributions differ between these populations, we performed our analysis for both scenarios. Results Dosing regimens of sacituzumab govitecan for the EU (< 50 kg: 400 mg, 50–80 kg: 600 mg, and > 80 kg: 800 mg) and US population (< 40 kg: 360 mg, 40–65 kg: 540 mg, 65–90 kg: 720 mg, and > 90 kg: 900 mg) were developed, based on weight bands. The geometric mean ratios for all pharmacokinetic outcomes were within the predefined equivalence boundaries, while the quantity of drug used was 21.5% and 19.0% lower for the EU and US scenarios, respectively. Conclusions With the alternative dosing proposal, an approximately 20% reduction in drug expenses for sacituzumab govitecan can be realized while maintaining an equivalent and more evenly distributed exposure throughout the body weight range, without notable increases in pharmacokinetic variability.


  • Open Access

    An innovative method to strengthen evidence for potential drug safety signals using Electronic Health Records

    by H. Abedian Kalkhoran, J. Zwaveling, F. van Hunsel, A. Kant

    Reports from spontaneous reporting systems (SRS) are hypothesis generating. Additional evidence such as more reports is required to determine whether the generated drug-event associations are in fact safety signals. However, underreporting of adverse drug reactions (ADRs) delays signal detection. Through the use of natural language processing, different sources of real-world data can be used to proactively collect additional evidence for potential safety signals. This study aims to explore the feasibility of using Electronic Health Records (EHRs) to identify additional cases based on initial indications from spontaneous ADR reports, with the goal of strengthening the evidence base for potential safety signals. For two confirmed and two potential signals generated by the SRS of the Netherlands Pharmacovigilance Centre Lareb, targeted searches in the EHR of the Leiden University Medical Centre were performed using a text-mining based tool, CTcue. The search for additional cases was done by constructing and running queries in the structured and free-text fields of the EHRs. We identified at least five additional cases for the confirmed signals and one additional case for each potential safety signal. The majority of the identified cases for the confirmed signals were documented in the EHRs before signal detection by the Dutch Medicines Evaluation Board. The identified cases for the potential signals were reported to Lareb as further evidence for signal detection. Our findings highlight the feasibility of performing targeted searches in the EHR based on an underlying hypothesis to provide further evidence for signal generation.


  • Open Access

    Effect of Busulfan and Treosulfan on Gonadal Function after Allogeneic Stem Cell Transplantation in Children and Adolescents with Nonmalignant Diseases Is Not Exposure-Dependent

    by M.Y. Eileen C. van der Stoep, Joëll E. Bense, Liselotte C. de Kloet, Erik G.J. von Asmuth, Anne P.J. de Pagter, Sabine E. Hannema, Henk-Jan Guchelaar, Juliette Zwaveling, Arjan C. Lankester


  • Open Access

    Application of Electronic Health Record Text Mining: Real-World Tolerability, Safety, and Efficacy of Adjuvant Melanoma Treatments

    by Sylvia A. van Laar, Ellen Kapiteijn, Kim B. Gombert-Handoko, Henk-Jan Guchelaar, Juliette Zwaveling

    Introduction: Nivolumab (N), pembrolizumab (P), and dabrafenib plus trametinib (D + T) have been registered as adjuvant treatments for resected stage III and IV melanoma since 2018. Electronic health records (EHRs) are a real-world data source that can be used to review treatments in clinical practice. In this study, we applied EHR text-mining software to evaluate the real-world tolerability, safety, and efficacy of adjuvant melanoma treatments. Methods: Adult melanoma patients receiving adjuvant treatment between January 2019 and October 2021 at the Leiden University Medical Center, the Netherlands, were included. CTcue text-mining software (v3.1.0, CTcue B.V., Amsterdam, The Netherlands) was used to construct rule-based queries and perform context analysis for patient inclusion and data collection from structured and unstructured EHR data. Results: In total, 122 patients were included: 54 patients treated with nivolumab, 48 with pembrolizumab, and 20 with D + T. Significantly more patients discontinued treatment due to toxicity on D + T (N: 16%, P: 6%, D + T: 40%), and X2 (6, n = 122) = 14.6 and p = 0.024. Immune checkpoint inhibitors (ICIs) mainly showed immune-related treatment-limiting adverse events (AEs), and chronic thyroid-related AE occurred frequently (hyperthyroidism: N: 15%, P: 13%, hypothyroidism: N: 20%, P: 19%). Treatment-limiting toxicity from D + T was primarily a combination of reversible AEs, including pyrexia and fatigue. The 1-year recurrence-free survival was 70.3% after nivolumab, 72.4% after pembrolizumab, and 83.0% after D + T. Conclusions: Text-mining EHR is a valuable method to collect real-world data to evaluate adjuvant melanoma treatments. ICIs were better tolerated than D + T, in line with RCT results. For BRAF+ patients, physicians must weigh the higher risk of reversible treatment-limiting AEs of D + T against the risk of long-term immune-related AEs.